

EPRA International Journal of Research and Development (IJRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

A CLINICAL STUDY ON MANAGEMENT OF UCCHARAKTACHAPA (ESSENTIAL HYPERTENSION) WITH TRIPHALA CHOORNA AND MEDHYA RASAYANA

¹Dr. Neha Agrawal, ²Prof. Dr Sarita Mohanta (Guide) ³Dr. Vinod Chandra Singh (Co-Guide)

¹M.D Scholar, Department of Roga Nidan Evam Vikriti Vigyan, Govt. Ayurvedic College & Hospital, Balangir, Odisha ²H.O.D Professor, Department of Roga Nidan Evam Vikriti Vigyan, Govt. Ayurvedic College & Hospital, Balangir, Odisha

³ Reader, Department of Roga Nidan Evam Vikriti Vigyan, Gopabandhu Ayurveda Mahavidyalaya, Puri, Odisha

Corresponding Author- Dr Neha Agrawal, M.D Scholar, P.G Department.of Roga Nidan Evam Vikriti Vigyan ,Govt. Ayurvedic College & Hospital, Balangir, Odisha

Article DOI: https://doi.org/10.36713/epra19982

DOI No: 10.36713/epra19982

ABSTRACT

Introduction- Hypertension is a major public health problem due to its prevalence all around the globe. There is no direct reference of Hypertension in any Ayurvedic classic. But, Acharya Charak has given a guideline to understand a new clinical entity not described by him in the Samhita. He narrates as "A Physician should not be puzzled while coming across a new clinical entity as it is not necessary that each and every disease should have nomenclature". That if a physician is unable to diagnose the disease, he should diagnose and treat the unknown disease by its Prakruti, Samuthan and Adhishtan.

Material and methods-This is a randomised open label clinical trial (single group). For this study patients of Essential Hypertension were selected randomly from the O.P.D. and I.P.D. of the Govt. Ayurvedic College and Hospital, Balangir.

Observation and Results-It had been observed that, 20(66.67%) patients were having Remarkable improvement, 8(26.67%) were having Moderate improvement, 2 (6.67%) were having mild improvement.

Conclusion- Clinical study concludes that Medhya Rasāyana and Triphala choorna was beneficial in Uccharaktachapa. No adverse effects were noticed during clinical trial in the group.

KEYWORDS- Uccharaktachapa, EHTN, SBP, DBP, Dosha, Dushya

INTRODUCTION

The 21stcentury is described as the age of anxiety and stress. This stress and strain of day today life affects one's body organs through several psycho-physical mechanisms causing many psychosomatic disorders. The "*Uccharaktachapa*" (Essential Hypertension) is one of such Diseases.

Though, *Ayurvedic* texts provide no straight reference to Essential Hypertension, here is an effort to understand the possible pathogenesis in terms of involved factors like *Doshas*, *Dushyas* etc. *Acharya Charak* has given a guideline to understand a new clinical entity not described by him in the *Samhita*. He narrates, a physician should not be puzzled while coming across a new clinical entity as it is not necessary that each and every disease should have nomenclature. That if a physician is unable to diagnose the disease, he should diagnose and treat the unknown disease by its *Prakruti*, *Samuthhan* and *Adhishtan*. He can design a treatment protocol for such disease, the disease by ruling out vitiated *dosha* out of *Tridoshas* and main *Nidan* factors.

Rasa Rakta dhatus are the chief involved Dushya foundin the observed symptomatology of the disease essential hypertension. Rasavaha, Raktavaha and Manovaha srotasa are involved in the generation of present disease. The Drug under trial itself is Rasayana in nature and hence it has to affect the main dhatus involved as Rasa and Rakta.



SJIF Impact Factor (2024): 8.675 | ISI I.F. Value: 1.241 | Journal DOI: 10.36713/epra2016 | ISSN: 2455-7838(Online)

EPRA International Journal of Research and Development (IJRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

AIM OF THE STUDY

■ To study the efficacy of *Triphala Choorna* and *Medhya Rasayana* in the management of *Uccharaktachapa* (Essential Hypertension)

MATERIAL AND METHODS

IEC number- 1799 /G.A.C & H of dated 29.08.2022 Ctri ref no-CTRI/2023/08/056873

Selection of Patients

This is an open label randomised clinical trial.30 numbers of patients suffering from Essential Hypertension (*Uccharaktachapa*) were taken for this study. They were randomly selected and screened by a special proforma which included details history taking, physical sign and symtoms and pathological investigation from OPD and IPD of Govt. Ayurvedic Hospital Balangir. The consent of patientwas also taken before clinical trial. The following inclusion and exclusion criteria had been followed for this study.

INCLUSION CRITERIA

- 1) Stage of Grade-1 Hypertension (Systolic BP-140-159, Diastolic BP-90-99mmHg)
- 2) Patients between 30-60 years age of either sex.
- 3) Patient not taking antihypertensive drugs.

EXCLUSION CRITERIA

Ischemic heart disease (IHD), coronary heart disease (CHD), coronary artery disease (CAD) and coarctation of aorta, Renal failure, Endocrine diseases, Hypertension with cerebral complications e.g Hypertensive encephalopathy, Cerebral heamorrhage, Convulsive seizure, Malignant hypertension, Pregnant and lactating mother, Patients age < 30 and > 60 years.

SELECTION OF DRUGS

Two medicines *Triphala choorna*² and *Medhya Rasayana*³ had been taken for the clinical trial. The drugs of both the medicines were identified by the experts of Dept of Dravyaguna which was approved by DRC and IEC of Govt. Ayurvedic college and Hospital, Balangir and Sambalpur University

Triphala Choorna was prepared as per GMP certified methods in Mini pharmacy of College under the supervision of expert of Rasashastra & Bhaisajya Kalpana. The sample of Triphala choorna was sent to Quality control Laboratories of Sambalpur University for analytical study. Medhya Rasayana Swarasa was prepared in the college campus by collecting the fresh drugs from the garden of GAC & H, Balangir on daily basis. The pharmacodynamics of the Triphala Choorna and Medhya Rasayana are mentioned below.

Table no 1- Showing the pharmacodynamics of drugs of Triphala and Medhya Rasayana

Rasa panchaka	Medhya Rasayana	Triphala choorna
Rasa	Tikta	Kashaya
Guna	Laghu	Ruksha
Virya	Sheeta	Anushna
Vipaka	Madhura	Madhura
Prabhaba	Rasayana	Rasayana,Medohara
Doshghnata	Tridoshahara, Rasayana	Tridoshahara, Rasayana

Dose

Triphala Choorna: 5gm once daily for 30 days at bed time.(30 minutes after food) with Lukewarm water. *Medhya Rasayana (Swarasa form)*:20ml twice daily in empty stomach for 30 days. (Morning and Evening) with *Madhu*

Assessment Criteria

The degree of severity was assessed by the grading score from 0-3 and data collected from patients on 10th day, 20th day and 30th day were assessed.



SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)

EPRA International Journal of Research and Development (IJRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

Systolic Blood pressure
150-159 2
Severe 3 Severe 3
1 90-95 1 96-99 2 Headache(Shirashoola)
Headache(Shirashoola)
Headache(Shirashoola) Absent 0 Mild 1 Moderate 2 Severe 3 Chest pain(Hridpida) Absent 0 Mild 1 Moderate 2 Severe 3 Vertigo(Bhrama) No dizziness or imbalance 0 Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Mild 1 Moderate 2 Severe 3 Chest pain(Hridpida) Absent 0 Mild 1 Moderate 2 Severe 3 Vertigo(Bhrama) No dizziness or imbalance 0 Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Moderate 2 Severe 3 Chest pain(Hridpida) Absent 0 Mild 1 Moderate 2 Severe 3 Vertigo(Bhrama) No dizziness or imbalance 0 Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Severe 3 Chest pain(Hridpida) Absent 0 Mild 1 Moderate 2 Severe 3 Vertigo(Bhrama) No dizziness or imbalance 0 Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Chest pain(Hridpida) Absent 0 Mild 1 Moderate 2 Severe 3 Vertigo(Bhrama) No dizziness or imbalance 0 Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Mild 1 Moderate 2 Severe 3 Vertigo(Bhrama) No dizziness or imbalance 0 Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Wertigo($Bhrama$)Moderate2Vertigo($Bhrama$)No dizziness or imbalance0Occasional and mild dizziness1Persistent or moderate2Persistent and severe3Breathlessness($Swasakrichhrata$)Absent0
Severe3Vertigo($Bhrama$)No dizziness or imbalance0Occasional and mild dizziness1Persistent or moderate2Persistent and severe3Breathlessness($Swasakrichhrata$)Absent0
Vertigo($Bhrama$)No dizziness or imbalance0Occasional and mild dizziness1Persistent or moderate2Persistent and severe3Breathlessness($Swasakrichhrata$)Absent0
Vertigo($Bhrama$)No dizziness or imbalance0Vertigo($Bhrama$)Occasional and mild dizziness1Persistent or moderate2Persistent and severe3Breathlessness($Swasakrichhrata$)Absent0
Occasional and mild dizziness 1 Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Persistent or moderate 2 Persistent and severe 3 Breathlessness(Swasakrichhrata) Absent 0
Breathlessness(Swasakrichhrata)Persistent and severe3Absent0
Breathlessness(Swasakrichhrata) Absent 0
Present after a moderate or heavy work 1
Present after a little work 2
Present in resting condition 3
Nausea(Hrillasa) Absent 0
Reduced feeding 1
Very reduced feeding 2
No feeding 3
Vomiting(chhardi) Absent 0
1 episode per 24hr 1
2-5 episode/24hr 2
6-10 episode/24hr 3
Swelling in legs(<i>Pada sotha</i>) No edema 0
Mild pitting edema (2mm)dissapper rapidly 1
Moderate pitting edema(4mm) disappear in 10-15 sec 2
Moderately severe pitting edema(6mm) last more than 1 min 3
Swelling under eye (Akshi sotha) Absent O
Present 1
1 ICOCIII
Haziness of vision (Tamo darshana) No tamodarsana 0
Haziness of vision (<i>Tamo darshana</i>) No tamodarsana Rare or occasionally tamodarshana(1-2 times in a month) 1
Haziness of vision (<i>Tamo darshana</i>) No tamodarsana Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) 2
Haziness of vision (Tamo darshana) No tamodarsana Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week 3
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Feeling burning sensation in hands and feets(No burning sensation O
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Teeling burning sensation in hands and feets(Hasta pada daha) No tamodarshana(1-2 times in a month) Often tamodarshana 2-3 times in a week No burning sensation Daha present occasionally
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Often tamodarshana 2-3 times in a week No burning sensation Hasta pada daha) Daha present occasionally Most of the time feeling burning sensation Most of the time feeling burning sensation
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Feeling burning sensation in hands and feets(No burning sensation Hasta pada daha) Daha present occasionally Most of the time feeling burning sensation Always feeling burning sensation Always feeling burning sensation
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Teeling burning sensation in hands and feets(No burning sensation Most of the time feeling burning sensation Always feeling burning sensation Always feeling burning sensation No Suptata O No Suptata
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Teeling burning sensation in hands and feets(Hasta pada daha) Daha present occasionally Most of the time feeling burning sensation Always feeling burning sensation Always feeling burning sensation Always feeling burning sensation Suptata present occssionaly
Haziness of vision (Tamo darshana) Rare or occasionally tamodarshana(1-2 times in a month) Frequent tamodarshana (1-2 times in a week) Often tamodarshana 2-3 times in a week Feeling burning sensation in hands and feets(No burning sensation Hasta pada daha) Daha present occasionally Most of the time feeling burning sensation Always feeling burning sensation Always feeling burning sensation Always feeling burning sensation No Suptata No Suptata



SJIF Impact Factor (2024): 8.675 | ISI I.F. Value: 1.241 | Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)

EPRA International Journal of Research and Development (IJRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

OBSERVATION AND RESULTS

The clinical study of 30 patients were observed based on Age, sex, marital status etc. along with incidence of Dasavidha parikshya (Table No-3) and the subjective and objective parameters. The percentage of improvement were also observed and assessed after clinical trial. After observation of subjective and objective parameters, the statistical analysis of parameters, was assessed by the help of statistical method (Table No-4, 5)

Table No 3- Incidence of *Dasavidha Parikshya* of Registered patients (n=30)

Sl.No.	Criteria	Category	Maximum Percentage
01	Prakriti	Vatapittaja	80.00%
02	Vikriti	Madhyambalavyadhi	63.33%
03	Sara	Madhyam sara	93.33%
04	Samhanana	Madhyama	80.00%
05	Pramana	Madhyama sarira	50.00%
06	Satwa	Madhyama	60.00%
07	Satmya	Madhyama	63.33%
08	Ahara Shakti	Madhyam	63.33%
09	Vyayama Shakti	Madhyam	50.00%
10	Vaya	Madhyavasta	100.00%

Table No 4- Showing the statistical Analysis of Subjective parameters (n=30)

Table No 4- Showing the statistical Analysis of Subjective parameters (n=50)									
Subjective parameters		Mean	Median	SD	SE	Wilcoxon W	P-Value	% Effect	Result
Headache	BT	1.33	2.00	0.92	0.17	-4.244 ^b	0.00002	77.50	Cia
	AT	0.30	0.00	0.47	0.09	-4.244°	0.00002	77.30	Sig
Chest pain	BT	0.27	0.00	0.45	0.08	-2.828 ^b	0.00468	100.00	C: a
_	AT	0.00	0.00	0.00	0.00	-2.828	0.00468	100.00	Sig
Vertigo	BT	0.60	1.00	0.62	0.11	-3.900 ^b	0.00010	04.44	C:-
	AT	0.03	0.00	0.18	0.03	-3.900°	0.00010	94.44	Sig
Breathlessness	BT	0.17	0.00	0.53	0.10	1 (22h	0.10247	NIA	NC
	AT	0.00	0.00	0.00	0.00	-1.633 ^b	0.10247	NA	NS
Nausea	BT	0.03	0.00	0.18	0.03	1 000h	0.21721	NIA	NG
	AT	0.00	0.00	0.00	0.00	-1.000 ^b	0.31731	NA	NS
Vomiting	BT	0.00	0.00	0.00	0.00	0000	1 00000	NIA	NG
	AT	0.00	0.00	0.00	0.00	.000°	1.00000	NA	NS
Swelling in legs and	BT	0.07	0.00	0.37	0.07	-1.000 ^b	0.21721	NIA	NC
under eyes	AT	0.03	0.00	0.18	0.03	-1.000°	0.31731	NA	NS
Haziness of vision	BT	0.47	0.00	0.68	0.12	2 207h	0.00124	05 71	C:-
	AT	0.07	0.00	0.25	0.05	-3.207 ^b	0.00134	85.71	Sig
feeling burning	BT	0.03	0.00	0.18	0.03				
sensation in hands and feet	AT	0.00	0.00	0.00	0.00	-1.000 ^b	0.31731	NA	NS
Numbness in hands	BT	0.63	0.00	0.76	0.14	2 557b	0.00028	04.21	G:-
and feet	AT	0.10	0.00	0.31	0.06	-3.557 ^b	0.00038	84.21	Sig



SJIF Impact Factor (2024): 8.675 | ISI I.F. Value: 1.241 | Journal DOI: 10.36713/epra2016 | ISSN: 2455-7838(Online)

EPRA International Journal of Research and Development (IJRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

Table No 5- Showing the statistical Analysis of Objective parameters (n=30)

Objective parameters		Mean	N	SD	SE	t-Value	P-Value	% Change	Result
SBP	BT	153.13	30	8.83	1.61	7.167	0.000	7.31	Ci.
	AT	141.93	30	6.59	1.20	/.10/	0.000	7.31	Sig
DBP	BT	94.93	30	2.50	0.46	0.277	0.000	2.44	G:-
	AT	91.67	30	2.17	0.40	9.277	0.000	3.44	Sig
Blood Urea	BT	24.57	30	6.03	1.10	1 772	0.097	10.00	NIC
	AT	21.87	30	4.10	0.75	1.772	0.087	10.99	NS
Sr. Creatinine	BT	0.84	30	0.26	0.05	0.014	0.422	2.50	NIC
	AT	0.87	30	0.15	0.03	-0.814	0.423	3.59	NS
RBS	BT	143.57	30	32.37	5.91	0.002	0.205	2.02	NG
	AT	139.23	30	25.17	4.59	-0.883	0.385	3.02	NS
Total Cholesterol	BT	174.50	30	30.41	5.55	5 242	0.000	5.50	G:-
	AT	164.80	30	25.20	4.60	5.243	0.000	5.56	Sig

DISCUSSION

Dosha Dusti Lakshana: In the present study *Bhrama, Shirashoola, urahshoola, Supti* were found to be major *Vata dusti Lakshanas*. *Tamodarshana, Daha* a major *Pitta* and *Rakta dusti Lakshana* and *Swasakrichhrata* as a major *Kapha Vata dusti Lakshanas*. These are the common complains observed in the patients of EHTN also. The data also reveals the fact that all the *Tridosha* were involved in the pathology of EHTN in *Taratamabhava*.

EFFECT OF THERAPY

EFFECT ON SIGN AND SYMPTOMS

It is very clear from the observation test drugs had excellent effect in reducing and relieving sign and symptoms.

Headache (*Shirashoola*)- The percentage of relief was 100 %, p-Value is less than 0.05 which was significant. *Vatadidosha* with *raktadusya* causes *shirashoola*⁴. The drugs like *Medhya rasayana* and *Triphala choorna* had *tridosha shamak* and *Bramhi* had *rakta prasadkara guna* along with this *Medhya rasayana* had antistress properties.

Chest pain (*Urashoola*)- On the symptom *Urahashoola*, improvement was observed with 100% and result was statistically significant. *Urahashula* is mentioned under the symptoms of Rasa *kshaya*⁵. Due to *Rasa kshaya* vitiated *Vyana vayu* causes pain in the chest. *Rasadi dhatu poshana* is the function of *rasayana* drugs.

Vertigo (Bhrama)- P-Value is less than 0.05. Hence, we can conclude that, effect observed in vertigo is significant. *Sharira Dosha Vata* and *Pitta* along with *Mano Dosha Raja* cause *Bhrama*. The *Rasayana* therapy has *Tridosha shamaka* property. And also it acts on *Mansika bhava* also, because of inclusion of *Medhya Rasayana* and *Triphala choorna*. So it has *Medhya, Rasayana* and *Tridosahara* effect, which remove the effect of vitiated *Raja Dosha*.

Brethlessness, feeling burning sensation in hands and feet, Nausea, Swelling in legs and under eyes- Although the result is not negative but as these symtoms were found in very less number of sample (1-2) so the result is not significant.

Haziness of vision - P-Value is less than 0.05. Hence, we can conclude that, effect observed in haziness of vision is significant. *Tamodarshana* in *Rakta Pradosajavyadhi*⁶: *medhya rasayana* found to be useful in disease of nerves and blood (rakta)

Numbness in hands and feet (*Hastapadasupti*)-P-Value is less than 0.05. Hence, we can conclude that, effect observed in *hastapadasupti* is significant. *Supti* comes under the *vataj nanatmaja vikara*⁷ and the drugs selected here was *tridhashamak* and neuroprotective.

Effect on Systolic and Diastolic blood pressure:

The systolic blood pressure and diastolic blood pressure decreased by 7.31% and 3.44% respectively. The results were statistically significant in lowering systolic and diastolic blood pressure.



SJIF Impact Factor (2024): 8.675 | ISI I.F. Value: 1.241 | Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)

EPRA International Journal of Research and Development (IIRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

Effect of therapy on Haemetological and Biochemical parameters

Random blood sugar level was statistically non significant as the value of it before treatment and after treatment was within normal range in all patients. And the drugs taken here were not affecting on blood sugar level.

Serum Creatinine and Blood Urea level was statistically non significant as the value of it before treatment and after treatment was within normal range in all patients.

S Cholestrol: S Cholesterol was reduced by 5.56%., P-Value is less than 0.05. Hence, we can conclude that, effect observed in Total Cholesterol is significant.

TOTAL EFFECT OF THERAPY

The clinical assessment was done basing on the sign and symptoms both subjective and objective parameters. After 30 days of treatment 2 patients (6.67%) got mild improvement, 8(26.67%) patients got Moderate improvement and 20(66.67%) patients got Remarkable improvement.

Table No 6- Showing clinical assessment of result in patients (n=30)

Overall Improvement	Frequency	Percentage
Remarkable Improvement	20	66.67%
Moderate Improvement	8	26.67%
Mild Improvement	2	6.67%
No Improvement	0	0.00%
TOTAL	30	100.00%

Graph 1



PROBABLE MODE OF ACTION

To understand the probable mode of action to main concepts can be taken as deliberation viz. 1. Rasapanchak of Medhya Rasayana and Triphala choorna. 2 The Samprapti ghatak of the disease. Medhya Rasyana and triphala choorna is Tikta. Kashaya so, it should act upto Rasa, Rakta dhatu along with their Srotas. It reduces the Aama in the Rasa Rakta and thereby viscosity of Rasa Rakta. This in turn reduces the pressure on the heart muscle and Rasa Vikshepana is ease to though. Laghu and Ruksha Guna of both Medhya Rasayana & Triphala choorna initially help Mandagni factor with Ushna Virya of the Triphala. The guna and virya of Drugs should collectively correct the Mandagni, and reduce the Dhamani Upalepa and virya pacify the vayu. In addition Madhur vipaka should help to pacify Vata. Collective mode of action of vipaka should have nourishing effect on disturbed Mana, as Madhur is the only nutrition to mind [Shadhindriyaprasadana]⁸. Besides this, Medhya rasayana are Balya in nature especially 'Nadibalya' (neurotonic). In recent years Medhya Rasayana has been reported to possess varying degree of anxiolytic activity that helps to reduce the stress. By virtue of all these properties, Medhya Rasayana acts on higher centers and improves the nervine control. The drug under trial itself is Rasayana in nature and hence it has to affect the main dhatus involved as Rasa and Rakta. EHTN being a purely lifestyle related unless and until life style modification executed. A permanent solution is not expectable. For this Acharyas have prescribed AACHAR RASAYANA as life style modification model. This role of AACHARA RASAYANA if implemented as long term project a complete resolution from Hypertension



SJIF Impact Factor (2024): 8.675 | ISI I.F. Value: 1.241 | Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)

EPRA International Journal of Research and Development (JIRD)

Volume: 10 | Issue: 1 | January 2025 - Peer Reviewed Journal

can be theoretically achievable but till then Medhya Rasayana like Neimittika Rasayan has to be an AAJASRIK RASAYANA i.e. to be taken lifelong.

CONCLUSION

At the verge of completion of this study the final conclusion can be drawn from the deductive reasoning of the relevant information and none deceiving data comprehended in the present study.

On objecting the cardinal sign and symptomatology of the disease to Avurvedic fundamentals, it is evident that there is predominance of Vata Pradhana Dosha its accompaniment with Rasa Rakta dusti. Role of mandagni is the principal source at the back of every disease that told by Acharyas, which causes uttapti of Aama. Aama in the Rasa Rakta Dhatu increases the viscosity and also pressure to combat this. Dhamani uplepa is one of the main incidences in Hypertension and is stated in Kapha Nanatmaja vvadhi. Hence, the Hypertension (EHTN) can be assigned as *Tridoshaja vyadhi* with predominance of *Vata*. Regarding the *Nidana* factors mainly genetic, dietary, psychological and environmental factors were observed practically, it may be, asserted that none of these factors influence the expression of the disease in segregation. They interact amongst each other in a variety of permutations to compliment and compound the resultant effect on this pathological phenomenon. Hence it is known as multifactorial disease.

Clinical study conclude that *Medhya Rasayana* and *Triphala choorna* is beneficial where systemic involvement is present with somatic symptoms like Shirashoola, Tamodarshana, Bhrama, Urahshoola, etc

As the study was conducted over a small sample, a similar study performed over a large sample for a longer period would have procured much sharper and more accurate results.

ORCID ID- Dr Neha Agrawal- https://orcid.org/ 0009-0004-9454-4355 Prof (Dr) Sarita Mohanta- https://orcid.org/ 0009-0007-0563-7130

REFERANCES

- 1. Charaka Samhita of Agnivesha, 'vidyotinitika' vol-1,Hindi Commentary by S.Sashtri published by Chaukhamba Bharati Academy Vanarasi, *Sutrasthana* (18/44-45)
- Sarangdhar Samhita, Hindi commentary by Bramhananda Tripathy, Published by Chaukhambabharatiacademy, Madhyama khanda (6/9).
- CharakaSamhita of Agnivesha, 'vidyotinitika' vol-2, Hindi Commentary by S.Sashtri published by Chaukhamba Bharati Academy Vanarasi, Chikitsa Sthana (1/3/30-31)
- Sushruta Samhita of Maharshi Sushrut. Edited with Ayurveda TatwaSandipika vol-1, Hindicommentary, Bykaviraj Ambikadutta Shastri, published by Chaukhmba Sanskrit Sansthan, Varanasi, Sutra sthan 21/20.
- Charaka Samhita of Agnivesha, 'vidyotinitika' vol-1, Hindi Commentary by S. Sashtri published by Chaukhamba Bharati Academy Vanarasi, Sutra sthan30
- 6. Charaka Samhita of Agnivesha, 'vidyotinitika' vol-1, Hindi Commentary by S. Sashtri published by Chaukhamba Bharati Academy Vanarasi, Sutra sthan (24/13)
- Charaka Samhita of Agnivesha, 'vidyotinitika' vol-1, Hindi Commentary by S. Sashtri published by Chaukhamba Bharati Academy Vanarasi, Sutra sthan (20/11)
- Charaka Samhita of Agnivesha, 'vidyotinitika' vol-1, Hindi Commentary by S. Sashtri published by Chaukhamba Bharati Academy Vanarasi, Sutrasthan (26/1)